ADVERTISEMENT
ADVERTISEMENT

FDA approves race-tested drug

The US Food and Drug Administration yesterday (December 17) linkurl:approved;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01757.html a beta blocker that I wrote about last month in an linkurl:article;http://www.the-scientist.com/news/display/53869 about the value of race-based medicine. The FDA's approval notice did not mention any particular race or ethnicity, and a linkurl:press release;http://www.frx.com/news/PressRelease.aspx?ID=1088188 from the drug's manufacturer noted that the drug, nebiv

kerry grens
Kerry Grens

Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at...

View full profile.


Learn about our editorial policies.

The US Food and Drug Administration yesterday (December 17) linkurl:approved;http://www.fda.gov/bbs/topics/NEWS/2007/NEW01757.html a beta blocker that I wrote about last month in an linkurl:article;http://www.the-scientist.com/news/display/53869 about the value of race-based medicine. The FDA's approval notice did not mention any particular race or ethnicity, and a linkurl:press release;http://www.frx.com/news/PressRelease.aspx?ID=1088188 from the drug's manufacturer noted that the drug, nebivolol, is effective in a broad range of patients. But the drug had been tested in a trial of African American patients only, because that group typically has a lower response to beta blockers than white patients. Nebivolol was effective in lowering blood pressure among the trial participants, but the researchers did not compare it to other treatments for hypertension. Nebivolol also underwent clinical trials that were not race-specific, and was effective in other groups that present challenges for treating hypertension, such as elderly and obese patients, Keith Ferdinand, the chief science officer at the Association of Black...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT